Polycystic Kidney Disease - Pipeline Review, H2 2018

Date: October 16, 2018
Pages: 100
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P26E4257DB1EN
Leaflet:

Download PDF Leaflet

Polycystic Kidney Disease - Pipeline Review, H2 2018
Polycystic Kidney Disease - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2018, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 9 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Polycystic Kidney Disease - Overview
Polycystic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Celgene Corp
Conatus Pharmaceuticals Inc
DiscoveryBiomed Inc
Genzyme Corp
IC-MedTech Inc
Ipsen SA
Kadmon Corp LLC
ManRos Therapeutics
Mironid Ltd
NovaTarg Therapeutics Inc
Q BioMed Inc
Reata Pharmaceuticals Inc
Polycystic Kidney Disease - Drug Profiles
(sodium ascorbate + menadione sodium bisulfite) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3586 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBM-43H11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Cystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibiglustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-8050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lixivaptan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
menadione sodium bisulfite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxypurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PKD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PKD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PKD-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit STAT3 for Oncology and Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesevatinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Sep 10, 2018: XORTX announces submission of Orphan Drug Designation Application
Aug 13, 2018: XORTX submits FDA pre-IND meeting documents
Jul 23, 2018: Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease
Jun 08, 2018: XORTX Announces Filing of FDA pre-IND Meeting Request Letter
May 25, 2018: Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
Nov 13, 2017: Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease
Nov 01, 2017: Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting
Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors
Jan 30, 2017: Mironid announces additional non-dilutive funding through an Early Stage Award from Innovate UK’s Biomedical Catalyst 2016
Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Polycystic Kidney Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H2 2018
Polycystic Kidney Disease - Pipeline by Celgene Corp, H2 2018
Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H2 2018
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H2 2018
Polycystic Kidney Disease - Pipeline by Genzyme Corp, H2 2018
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H2 2018
Polycystic Kidney Disease - Pipeline by Ipsen SA, H2 2018
Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H2 2018
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2018
Polycystic Kidney Disease - Pipeline by Mironid Ltd, H2 2018
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H2 2018
Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H2 2018
Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, H2 2018
Polycystic Kidney Disease - Dormant Projects, H2 2018
Polycystic Kidney Disease - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Polycystic Kidney Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Angion Biomedica Corp
Celgene Corp
Conatus Pharmaceuticals Inc
DiscoveryBiomed Inc
Genzyme Corp
IC-MedTech Inc
Ipsen SA
Kadmon Corp LLC
ManRos Therapeutics
Mironid Ltd
NovaTarg Therapeutics Inc
Q BioMed Inc
Reata Pharmaceuticals Inc
Skip to top


Ask Your Question

Polycystic Kidney Disease - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: